ECM-targeted theranostic treatment for metastatic lung cancer
Official title: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer
Funded at Matrisome Bio, INC. · NIH-11419641 · Data updated 2026-11-12
A new therapy aims to deliver cancer-fighting agents directly to the tumor environment in people with metastatic lung cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Matrisome Bio, INC. NIH-funded |
| Lab location | 1 site (Cambridge, UNITED STATES) |
| Project start | September 23, 2025 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,013,647 |
| NIH project number | 5R44CA298532-02 |
| Project ID | NIH-11419641 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with metastatic lung cancer who may benefit from targeted therapies addressing the tumor microenvironment.
✕Less likely to help
Patients whose cancer does not depend on ECM components or where delivery to metastases is not feasible may see limited benefit.
What this research studies
This project focuses on a novel approach that targets the extracellular matrix around tumors to guide treatment to where cancer spreads. Researchers are developing nanobody-based drugs that stay in the disease site longer, potentially improving delivery and effectiveness without needing to attack tumor cells directly. The work involves preclinical and early development steps to test safety, distribution in the body, and how well these agents reach metastatic lung tumors. If successful, this strategy could complement or offer an alternative to existing therapies for advanced lung cancer.
Why it matters
Potential benefit: If successful, patients with metastatic lung cancer could receive more targeted therapy with potentially better effectiveness and fewer side effects.
How similar studies have gone: Previous work has shown promise with ECM-targeted strategies in cancer, but this approach is still in early development and needs further validation.
Where this research is happening
-
Matrisome Bio, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Jailkhani, Noor — Matrisome Bio, INC.
- Study coordinator: Jailkhani, Noor
Related research
Other NIH-funded projects on the same topics.
-
Targeted T cell therapy for metastatic lung cancer with mutated KRAS
A personalized therapy uses engineered T cells to attack KRAS-mutated metastatic non-small cell lung cancer in patients.
-
Supportive Care for Lung Cancer Patients with Targeted Therapy
A patient-facing program tests a palliative care approach tailored for people living with oncogene-driven metastatic lung cancer to help with uncertainty, self-care, and discussions about goals and values.
-
LiveWell — DBT skills training for people living with metastatic lung cancer
This is an eight-session, one-on-one online program that teaches Dialectical Behavior Therapy skills to help people living with metastatic lung cancer handle distress, symptoms, and relationships.
-
Engineered T cells that target KRAS-mutated metastatic lung cancer
This project uses specially engineered immune cells to try to find and kill metastatic lung cancers that have KRAS gene mutations.
-
Using aerosolized therapy to treat metastatic lung cancer
This study is exploring a new way to treat metastatic lung cancer by using a special inhaled therapy that may help wake up genes in cancer cells, and it's designed for patients looking for more effective treatment options.
-
Improving care for patients with advanced lung cancer using personalized approaches
This study is looking to improve support for people with metastatic lung cancer who have certain genetic mutations by testing a new way to help them feel more comfortable and make better decisions about their care, based on what they and their doctors think is important.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.